|
1) Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006; 109: 137-61
|
|
|
|
2) Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995; 12: 413-20
|
|
|
|
|
|
3) Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005; 22: 11-23
|
|
|
|
|
|
4) Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998; 34: 429-55
|
|
|
|
|
|
5) Johnson AG, Rigby RJ, Taylor PJ, et al. The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. Clin Pharmacol Ther. 1999; 66: 492-500
|
|
|
|
|
|
6) Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007; 46: 13-58
|
|
|
|
|
|
7) Takekuma Y, Kakiuchi H, Yamazaki K, et al. Difference between pharmacokinetics of mycophenolic acid (MPA) in rats and that in human is caused by different affinities of MRP2 to a glucuronized form. J Pharm Pharmaceut Sci. 2007; 10: 71-85
|
|
|
|
|
|
8) Naesens M, Kuypers DR, Verbeke K, et al. Multidrug resistance protein 2 genetic polymorphisms influence mycophenolic acid exposure in renal allograft recipients. Transplantation. 2006; 82: 1074-84
|
|
|
|
|
|
9) Miura M, Satoh S, Inoue K, et al. Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007; 63: 1161-9
|
|
|
|
|
|
10) Jiao Z, Ding JJ, Shen J, et al. Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. Br J Clin Pharmacol. 2008; 65: 893-907
|
|
|
|
|
|
11) Van Mourik IDM, Thomson M, Kelly DA. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. Liver Transpl Surg. 1999; 5: 107-11
|
|
|
|
|
|
12) Paine MF, Schmiedlin-Ren P, Watkins PB. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab Dispos. 1999; 27: 360-4
|
|
|
|
|
|
13) Mouly S, Paine MF. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res. 2003; 20: 1595-9
|
|
|
|
|
|
14) Komura H, Iwaki M. Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci. 2007; 97: 1775-800
|
|
|
|
|
|
15) Kato M, Chiba K, Hisaka A, et al. The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein‐quantitative analysis based on information from the literature. Drug Metab Pharmacokin. 2003; 18: 365-72
|
|
|
|
|
|
16) Masuda S, Uemoto S, Goto M, et al. Tacrolimus therapy according to mucosal MDR1 levels in small-bowel transplant recipients. Clin Pharmacol Ther. 2004; 75: 352-61
|
|
|
|
|
|
17) Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther. 2006; 112: 184-98
|
|
|
|
|
|
18) Niemi M, Backman JT, Fromm MF, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet. 2003; 42: 819-50
|
|
|
|
|
|
19) Englund G, Jacobson A, Rorsman F, et al. Efflux transporters in ulcerative colitis: decreased expression of BCRP (ABCG2) and Pgp (ABCB1). Inflamm Bowel Dis. 2007; 13: 291-7
|
|
|
|
|
|
20) Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004; 127: 26-40
|
|
|
|
|
|
21) Maezono S, Sugimoto K, Sakamoto K, et al. Elevated blood concentrations of calcineurin inhibitors during diarrheal episode in pediatric liver transplant recipients: involvement of the suppression of intestinal cytochrome P450 3A and P-glycoprotein. Pediatr Transplant. 2005; 9: 315-23
|
|
|
|
|
|
22) Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006; 109: 1-11
|
|
|
|
|
|
23) Naud J, Michaud J, Boisvert C, et al. Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther. 2007; 320: 978-85
|
|
|
|
|
|
24) Mori N, Yokooji T, Murakami T. Fate of quinidine, a P-glycoprotein substrate, in the gastrointestinal tract after oral administration in rats. Pharmazie. 2008; 63: 241-4
|
|
|
|
|
|
25) Casado FJ, Lostao MP, Aymerch I, et al. Nucleoside transporters in absorptive epithelia. J Physiol Biochem. 2002; 58: 207-16
|
|
|
|
|
|
26) Lu H, Chen C, Klaassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos. 2004; 32: 1455-61
|
|
|
|
|
|
27) Honda M, Itoh H, Suzuki T, et al. Population pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Biol Pharm Bull. 2006; 29: 2460-4
|
|
|
|
|
28) Stypinski D, Obaidi M, Combs M, et al. Safety, tolerability and pharmacokinetics of higher-dose mizoribine in healthy male volunteers. Br J Clin Pharmacol. 2006; 63: 459-68
|
|
|
|
|
|
29) Okada M, Suzuki T, Nakashima M, et al. The nucleotide derivatives inosine and inosinic acid inhibit intestinal absorption of mizoribine in rats. Eur J Pharmacol. 2006; 531: 140-4
|
|
|
|
|
|
30) Mori N, Yokooji T, Kamio Y, et al. Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats. Eur J Pharmacol. 2008; 586: 52-8
|
|
|
|
|
|
31) Meier Y, Elooranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007; 35: 590-4
|
|
|
|
|
|
32) Lu H, Chen C, Klassen C. Tissue distribution of concentrative and equilibrative nucleoside transporters in male and female rats and mice. Drug Metab Dispos. 2004; 32: 1455-61
|
|
|
|
|
|
33) Murakami T, Takano M. Intestinal efflux transporters and drug absorption. Expert Opin Drug Metab Toxicol. 2008; 4: 923-39
|
|
|
|
|
|
34) Qiu A, Jansen M, Sakaris A, et al. Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption. Cell. 2006; 127: 917-28
|
|
|
|
|
|
35) Nakai Y, Inoue K, Abe N, et al. Functional characterization of human proton-coupled folate transporter/heme carrier protein 1 heterologously expressed in mammalian cells as a folate transporter. J Pharmacol Exp Ther. 2007; 322: 469-76
|
|
|
|
|
|
36) Inoue K, Nakai Y, Ueda S, et al. Functional characterization of PCFT/HCP1 as the molecular entity of the carrier-mediated intestinal folate transport system in the rat model. Am J Physiol. 2008; 294: G660-8
|
|
|
|
|
|
37) Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004; 64: 5804-11
|
|
|
|
|
|
38) Yokooji T, Murakami T, Yumoto R, et al. Role of intestinal efflux transporters in the intestinal absorption of methotrexate in rats. J Pharm Pharmacol. 2007; 59: 1263-70
|
|
|
|
|
|
39) Murakami T, Yumoto R, Nagai J, et al. Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states. Pharmazie. 2002; 57: 102-7
|
|
|
|
|
|
40) Yumoto R, Murakami T, Takano M. Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. Pharm Res. 2003; 20: 765-71
|
|
|
|
|
|
41) Yokooji T, Murakami T, Yumoto R, et al. Function of multidrug resistance-associated protein 2 in acute hepatic failure rats. Eur J Pharmacol. 2006; 546: 152-60
|
|
|
|
|